CL Stock Analysis: Colgate-Palmolive | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 73.874m USD | 12M Return: 20.8% | US1941621039 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 436M
EPS Trend: 93.9%
Qual. Beats: 14
Rev. Trend: 91.3%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Colgate-Palmolive Company (NYSE: CL) is a global consumer products manufacturer founded in 1806 and headquartered in New York. It operates through two segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care segment produces toothpaste, toothbrushes, hand soaps, shampoos, deodorants, dishwashing detergents, household cleaners, and skin health products, marketed under brands such as Colgate, Palmolive, Toms of Maine, Irish Spring, Softsoap, Ajax, and Fabuloso. The Pet Nutrition segment offers everyday and therapeutic pet foods primarily under the Hills Science Diet and Hills Prescription Diet brands, distributed through pet supply retailers, veterinarians, and eCommerce channels.
As a large-cap Consumer Staples company in the Household Products sub-industry, Colgate-Palmolive competes in a defensive sector typically characterized by stable demand across economic cycles. Its business model centers on a diversified portfolio of established global brands, broad international distribution, and recurring purchases of low-priced essential goods such as oral care, cleaning, and pet nutrition products.
- Hills Pet Nutrition outpaces oral care segment growth
- Latin America FX headwinds pressure reported revenue
- Premium skincare acquisitions lift gross margins
| Net Income: 2.04b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 3.69 > 1.0 |
| NWC/Revenue: 0.76% < 20% (prev -3.90%; Δ 4.66% < -1%) |
| CFO/TA 0.27 > 3% & CFO 4.46b > Net Income 2.04b |
| Net Debt (7.05b) to EBITDA (3.84b): 1.84 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (805.8m) vs 12m ago -1.31% < -2% |
| Gross Margin: 60.42% > 18% (prev 60.57%; Δ -0.15% > 0.5%) |
| Asset Turnover: 122.9% > 50% (prev 114.5%; Δ 8.39% > 0%) |
| Interest Coverage Ratio: 12.53 > 6 (EBIT TTM 3.20b / Interest Expense TTM 255.0m) |
| A: 0.01 (Total Current Assets 6.31b - Total Current Liabilities 6.15b) / Total Assets 16.8b |
| B: 1.61 (Retained Earnings 27.1b / Total Assets 16.8b) |
| C: 0.19 (EBIT TTM 3.20b / Avg Total Assets 17.1b) |
| D: 0.01 (Book Value of Equity 236.0m / Total Liabilities 16.2b) |
| Altman-Z'' = 6.59 = AAA |
| DSRI: 1.05 (Receivables 1.96b/1.77b, Revenue 21.0b/20.0b) |
| GMI: 1.00 (GM 60.57% / 60.42%) |
| AQI: 0.88 (AQ_t 0.35 / AQ_t-1 0.40) |
| SGI: 1.05 (Revenue 21.0b / 20.0b) |
| TATA: -0.14 (NI 2.04b - CFO 4.46b) / TA 16.8b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of October 20, 2026, the stock is trading at USD 93.39 with a total of 3,475,267 shares traded. Over the past week, the price has changed by +3.79%, over one month by +8.27%, over three months by +1.59% and over the past year by +20.75%.
Current recommended Stop Loss: 91.00 (which is 2.6% or 1.4 ATR below the current price).
Colgate-Palmolive has received a consensus analysts rating of 3.95. Therefore, it is recommended to buy CL.
- StrongBuy: 7
- Buy: 6
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 98.1 | 5% |
P/E Trailing = 35.3702
P/E Forward = 20.9644
P/S = 3.51
P/B = 290.2587
P/EG = 1.566
Revenue TTM = 21.0b USD
EBIT TTM = 3.20b USD
EBITDA TTM = 3.84b USD
Long Term Debt = 7.82b USD (from longTermDebt, last quarter)
Short Term Debt = 34.0m USD (from shortTermDebt, last quarter)
Debt = 8.42b USD (from shortLongTermDebtTotal, last quarter) + Leases 566.0m
Net Debt = 7.05b USD (calculated: Debt 8.42b - CCE 1.37b)
Enterprise Value = 80.9b USD (73.9b + Debt 8.42b - CCE 1.37b)
Interest Coverage Ratio = 12.53 (Ebit TTM 3.20b / Interest Expense TTM 255.0m)
EV/FCF = 20.98x (Enterprise Value 80.9b / FCF TTM 3.86b)
FCF Yield = 4.77% (FCF TTM 3.86b / Enterprise Value 80.9b)
FCF Margin = 18.33% (FCF TTM 3.86b / Revenue TTM 21.0b)
Net Margin = 9.68% (Net Income TTM 2.04b / Revenue TTM 21.0b)
Gross Margin = 60.42% ((Revenue TTM 21.0b - Cost of Revenue TTM 8.33b) / Revenue TTM)
Gross Margin QoQ = 61.48% (prev 60.59%)
Tobins Q-Ratio = 4.82 (Enterprise Value 80.9b / Total Assets 16.8b)
Interest Expense / Debt = 3.03% (Interest Expense 255.0m / Debt 8.42b)
Taxrate = 26.52% (780.0m / 2.94b)
NOPAT = 2.35b (EBIT 3.20b * (1 - 26.52%))
Current Ratio = 1.03 (Total Current Assets 6.31b / Total Current Liabilities 6.15b)
Debt / Equity = 35.69 (Debt 8.42b / totalStockholderEquity, last quarter 236.0m)
Debt / EBITDA = 1.84 (Net Debt 7.05b / EBITDA 3.84b)
Debt / FCF = 1.83 (Net Debt 7.05b / FCF TTM 3.86b)
Total Stockholder Equity = 496.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.89% (Net Income 2.04b / Total Assets 16.8b)
RoE = 410.7% (Net Income TTM 2.04b / Total Stockholder Equity 496.0m)
RoCE = 38.42% (EBIT 3.20b / Capital Employed (Equity 496.0m + L.T.Debt 7.82b))
RoIC = 24.40% (NOPAT 2.35b / Invested Capital 9.62b)
WACC = 4.54% (E(73.9b)/V(82.3b) * Re(4.80%) + D(8.42b)/V(82.3b) * Rd(3.03%) * (1-Tc(0.27)))
Discount Rate = 4.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.32 | Cagr: -1.09%
[DCF] Terminal Value 77.89% ; FCFF base≈3.66b ; Y1≈4.18b ; Y5≈6.08b
[DCF] Fair Price = 106.1 (EV 91.6b - Net Debt 7.05b = Equity 84.6b / Shares 797.2m; r=8.35% [WACC [floored]]; 5y FCF grow 14.48% → 2.50% )
EPS Correlation: 93.92 | EPS CAGR: 6.49% | SUE: 3.86 | # QB: 14
Revenue Correlation: 91.33 | Revenue CAGR: 2.65% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.93 | Chg30d=-0.17% | Revisions=+0% | Analysts=17
EPS current Year (2026-12-31): EPS=3.87 | Chg30d=-0.20% | Revisions=-50% | GrowthEPS=+4.8% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=4.09 | Chg30d=-0.49% | Revisions=-57% | GrowthEPS=+5.7% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: -58% (up=1, down=8)